NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $210 | -100.0% | 3,498 | -58.7% | 0.02% | -76.1% |
| Q2 2022 | $588,000 | +142.0% | 8,462 | +288.0% | 0.09% | +114.6% |
| Q3 2020 | $243,000 | +20.3% | 2,181 | -9.1% | 0.04% | +70.8% |
| Q4 2019 | $202,000 | -37.5% | 2,400 | -44.4% | 0.02% | -45.5% |
| Q3 2019 | $323,000 | -70.4% | 4,320 | -75.0% | 0.04% | -63.9% |
| Q2 2019 | $1,092,000 | +2.4% | 17,265 | -22.0% | 0.12% | +13.0% |
| Q1 2019 | $1,066,000 | +167.8% | 22,136 | +86.0% | 0.11% | +134.8% |
| Q4 2018 | $398,000 | -74.0% | 11,900 | -59.2% | 0.05% | -45.9% |
| Q3 2018 | $1,530,000 | -1.2% | 29,200 | -41.0% | 0.08% | +10.4% |
| Q2 2018 | $1,549,000 | +248.1% | 49,500 | +142.6% | 0.08% | +220.8% |
| Q1 2018 | $445,000 | -21.7% | 20,400 | -27.4% | 0.02% | -31.4% |
| Q4 2017 | $568,000 | +18.8% | 28,100 | +16.6% | 0.04% | +6.1% |
| Q3 2017 | $478,000 | +49.4% | 24,100 | +68.5% | 0.03% | +106.2% |
| Q4 2015 | $320,000 | – | 14,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
| Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
| HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
| Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
| MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
| Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
| Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
| Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
| Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |